Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate

BACKGROUND: Loss of bronchoprotection (LOBP) with a regularly used long-acting β(2)-adrenergic receptor agonist (LABA) is well documented. LOBP has been attributed to β(2)-adrenergic receptor (B2AR) downregulation, a process requiring farnesylation, which is inhibited by alendronate. OBJECTIVE: We s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Allergy Clin Immunol
Auteurs principaux: Cardet, Juan Carlos, Jiang, Xiaofeng, Lu, Quan, Gerard, Norma, McIntire, Kristen, Boushey, Homer A., Castro, Mario, Chinchilli, Vernon M., Codispoti, Christopher D., Dyer, Anne-Marie, Holguin, Fernando, Kraft, Monica, Lazarus, Stephen, Lemanske, Robert F., Lugogo, Njira, Mauger, Dave, Moore, Wendy C., Moy, James, Ortega, Victor E., Peters, Stephen P., Smith, Lewis J., Solway, Julian, Sorkness, Christine A., Sumino, Kaharu, Wechsler, Michael E., Wenzel, Sally, Israel, Elliot
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6950766/
https://ncbi.nlm.nih.gov/pubmed/30872116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2019.01.049
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires